Breaking World Pharma News: Meeflon ® 500 (Micronized purified flavonoid fraction) Tablets, Use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Meeflon ® 500 (Micronized purified flavonoid fraction) Tablets, An oral phlebotropic drug consisting of 90% micronised diosmin and 10% flavonoids expressed as hesperidin, improves venous tone and lymphatic drainage, and reduces capillary hyperpermeability by protecting the microcirculation from inflammatory processes. Use in chronic venous insufficiency, venous ulcers and haemorrhoids.

Meeflon® 500 (Micronized purified flavonoid fraction) Tablets
is a micronized purified flavonoid fraction containing 90% diosmin and
10% other flavonoids expressed as hesperidin.

Meeflon® 500 - This pill is a venotonic (it increases venous tone) and a vasculoprotector (it increases resistance in small blood vessels).
It is recommended for treating venous circulation disorders (swollen legs, pain, restless legs) and for treating acute hemorrhoidal attack.
Dosage:
For venous insufficiency, the dosage is 2 tablets daily. For acute hemorrhoidal attack, the dosage is 6 tablets daily
for 4 days, followed by 4 tablets daily over the next 3 days.
Side effect: Possible side effects include routine gastric disorders and neurovegetative disorders.

Micronised purified flavonoid fraction (MPFF) [Meeflon 500 mg], an oral phlebotropic drug consisting of 90% micronised diosmin and 10% flavonoids expressed as hesperidin, improves venous tone and lymphatic drainage, and reduces capillary hyperpermeability by protecting the microcirculation from inflammatory processes. The absorption of diosmin is improved by its micronisation to particles with a diameter <2 microm. Compared with placebo, MPFF 500 mg twice daily significantly decreased ankle or calf circumference, and improved many symptoms of chronic venous insufficiency (CVI) and plethysmographic parameters in two randomised, double-blind, 2-month studies. Improvement in symptoms was parallelled by an improvement in health-related quality of life in a nonblind, 6-month trial. Significantly more venous leg ulcers </=10 cm in diameter completely healed with MPFF 500 mg twice daily plus standard management (compression and local treatment) for 2-6 months than with standard management alone or with placebo in a nonblind and a double-blind trial. The addition of MPFF to standard management was cost effective in a retrospective pharmacoeconomic analysis of the 6-month trial. Compared with placebo, the duration and/or intensity of individual symptoms of grade 1 or 2 acute internal haemorrhoids improved significantly with 3 tablets of MPFF 500 mg twice daily for 4 days then 2 tablets of MPFF 500 mg twice daily for 3 days. Two tablets of MPFF 500 mg daily for 60 or 83 days reduced the frequency, duration and/or severity of acute haemorrhoidal symptoms and improved the overall signs and symptoms of chronic (recurrent) haemorrhoids compared with placebo. Compared with a control group, MPFF significantly reduced the risk of secondary bleeding after elective haemorrhoidectomy. In clinical trials, MPFF had a tolerability profile similar to that of placebo; the most frequently reported adverse events were gastrointestinal and autonomic in nature. In conclusion, MPFF is a well established and well tolerated treatment option in patients with CVI, venous ulcers, or acute or chronic internal haemorrhoids. MPFF is indicated as a first-line treatment of oedema and the symptoms of CVI in patients in any stage of the disease. In more advanced disease stages, MPFF may be used in conjunction with sclerotherapy, surgery and/or compression therapy, or as an alternative treatment when surgery is not indicated or is unfeasible. The healing of venous ulcers </=10 cm in diameter is accelerated by the addition of MPFF to standard venous ulcer management. MPFF may reduce the frequency, duration and/or intensity of symptoms of grade 1 or 2 acute internal haemorrhoids, and also the severity of the signs and symptoms of chronic haemorrhoids.

Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study******

Abstract

Purpose : The purpose of this study was to determine the effects of a micronized purified flavonoid fraction treatment on surface expression of leukocyte adhesion molecules in chronic venous disease (CVD). Methods : Twenty patients with chronic venous disease were assessed with the use of clinical and Duplex scanning criteria. Consenting patients were treated for 60 days with a micronized purified flavonoid fraction treatment (500 mg twice daily). Blood was collected from a foot vein immediately before the start of treatment and within 1 week after the treatment was stopped. Neutrophil and monocyte surface adhesion molecule expression was determined by flow cytometry using the monoclonal antibodies to CD11b and CD62L. Results : Neutrophil CD11b (248:212), monocyte CD11B (204:190), neutrophil CD62L (130:97 [P =.002]), and monocyte CD62L (170:121 [P =.03]) were determined, respectively, before and after treatment. All values are arbitrary units and represent median values. Conclusion : Micronized purified flavonoid fraction treatment for 60 days seems to decrease the surface expression of CD62L by neutrophils and by monocytes. The clinical significance of this finding needs to be explored further. It is feasible to use changes in the levels of these molecules as a marker for response to therapy in chronic venous disease. (J Vasc Surg 2000;31:456-61.)

Address Russian State Medical University

1, Ostrovityanova Street

City/town Moscow

Zip/Postcode 117997

Country Russian Federation

Sponsor Institut de Recherches Internationales Servier (France)

Address 50 rue Carnot

City/town Suresnes

Zip/Postcode 92284

Country France

Micronized Purified Flavonoid Fraction and the Treatment of Chronic Venous Insuf.

Introduction:

The standard treatments for venous diseases of the lower limb include compression bandaging and stockings as well as surgical removal of varicose veins. There is a number of conditions in which these conventional treatments are ineffective, particularly in the management of leg ulceration. Drug treatments for healing venous leg ulcers have yet to be developed to the stage of good clinical efficacy, but may assist in the management of patients. Flavonoid drugs have been widely used in the management of the symptoms of venous disease for many years and have recently been studied in some detail to assess their effects on the microcirculation. Work in animal models of ischemia/reperfusion (I/R) show that micronized purified flavonoid fraction (MPFF) modulates leukocyte adhesion and prevents endothelial damage. Similar biochemical effects have been observed in patients with venous disease and may explain the efficacy of this drug in the management of edema and other symptoms of venous disease. There is some evidence that MPFF promotes venous leg ulcer healing.

Keywords:

ambulatory venous hypertension, flavonoid treatment, microcirculation, neutrophils, varicose ulceration, varicose veins.

Daflon 500 (Rutaceae) - 500mg (10 Tablets)

Brand Name: Meeflon 500

Generic Name: Rutaceae

Form: Tablets

Manufacturer: Taj Pharmaceuticals Ltd.

What is Meeflon 500?

Meeflon 500 is a unique micronized purified flavonoid fraction, extracted from citrus fruit plants. It is mainly prescribed for patients who cannot get the necessary amounts in their regular diets. It is generally used to treat conditions caused by chronic venous disease (CVD) like swollen legs, nocturnal cramps and varicose veins. Some people may also use it to treat acute hemorrhoidal attacks and prevents further bleeding episodes.

How is Meeflon 500 used?

Meeflon 500 is usually taken orally twice daily, once in the afternoon and once in the evening. The tablets should be taken with some food along with some fluids. Contact a doctor for the correct dosage and length of treatment as it will depend on the condition being treated and the patient�s response to the therapy. The tablet should be swallowed whole and not crushed, chewed or cut.

Adverse effects

Meeflon 500 may cause unwanted side effects such as:

Difficulty breathing or swallowing

Unusual taste in mouth

Headaches

Upset stomach

Contact a doctor immediately should side effects persist or worsen.

Warnings

Immediately proceed to your nearest emergency department if you suffer an allergic reaction. Symptoms usually associated with such a reaction include difficulty breathing or swallowing, chest tightness, swelling, skin rashes, and hives.

Daflon 500 is not always suitable for all patients. Always consult your health care provider prior to using this medication if you are pregnant, breastfeeding, trying to conceive, using any other medication (prescription or non-prescription), using any herbal products or supplements, or if you have any allergies or other health problems.

The correct dosage and prescription commonly depend on the patient and the condition being treated. Do not adjust your dosage without the approval of your health care provider. This product is only for use as prescribed and instructed.

Details

SKU 345345434444

Our price: $5.11

Use in pregnancy: Experimental studies in animal have not demonstrated any teratogenic effect and no harmful effects have been reported in human to date.
Use in lactation: In absence of data concerning the diffusion into breast milk, breast-feeding is not recommended during treatment.
• In hemorrhoidal disease:
For acute disease: 6 tablets daily for 4 days, then 4 tablets daily for 3 days
For chronic disease: 2 tablets daily
• In chronic venous disease: 2 tablets daily
• For Lymphedema : 2 tablets daily

Meeflon Tablet: Each film coated tablet contains micronized purified flavonoid fraction 500 mg: Diosmin BP 450 mg & Hesperidin INN 50 mg.

© 2014. Taj Pharma Ltd. All rights reserved.